Support Centre
21 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Does Lyclear® spray away work better than permethrin to cure head lice?
DOI 10.1186/ISRCTN96469780
ClinicalTrials.gov identifier
EudraCT number
Public title Does Lyclear® spray away work better than permethrin to cure head lice?
Scientific title A randomised, controlled, assessor-blind, clinical trial to investigate superiority of Lyclear® spray away (ParaNix® spray) compared with Infectopedicul® permethrin 0.5% lotion in the treatment of head lice
Acronym N/A
Serial number at source CTOM01, version 1.3 (18/02/2008)
Study hypothesis To investigate superiority of Lyclear® spray away (ParaNix® spray) over Infectopedicul® in the eradication of head lice and prevention of hatching of louse eggs and to compare the products for safety, ease of application and participant acceptability.
Lay summary
Ethics approval Leeds (West) Research Ethics Committee. Date of approval: 04/03/2008 (ref: 08/H1307/18)
Study design Randomised, controlled, assessor blind, parallel group study.
Countries of recruitment United Kingdom
Disease/condition/study domain Infestation with head lice (Pediculus capitis)
Participants - inclusion criteria 1. Both males and females, aged 2 years and over with no upper age limit
2. Participants who upon examination, are confirmed to have live head lice
3. Participants who give written informed consent, or if the participant is under 16 years of age whose parent/guardian gives written informed consent to participate in the study
4. Participants who will be available for home visits by Medical Entomology Centre (MEC) study team members over the 14 days following first treatment
Participants - exclusion criteria 1. Participants with a known sensitivity to any of the ingredients in Lyclear® spray away (ParaNix® spray) or Infectopedicul® lotion
2. Participants with asthma or a similar respiratory condition
3. Participants with a secondary bacterial infection of the scalp (e.g. impetigo) or who have a long term scalp condition (e.g. psoriasis of the scalp)
4. Participants who have been treated with other head lice products within the previous two weeks
5. Participants who have bleached hair, or hair that has been colour treated or permanently waved within the previous four weeks (wash in/wash out colours are acceptable)
6. Participants who have been treated with the antibiotics co-trimoxazole or trimethoprim within the previous four weeks, or who are currently taking such a course
7. Pregnant or nursing mothers
8. Participants who have participated in another clinical study within 1 month before entry to this study
9. Participants who have already participated in this clinical study
Anticipated start date 23/03/2008
Anticipated end date 31/05/2008
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 100
Interventions The participants will be randomly allocated to the two groups in equal numbers.

Group 1: Participants will be treated with Lyclear® spray away (ParaNix® spray; topical) containing:
Active: Illicium verum (star anise) oil, caprylic/capric triglyceride (fractionated coconut oil derivative), cananga odorata (ylang-ylang) oil
Excipients: Propan-2-ol

Group 2: Participants will be treated with Infectopedicul® lotion (topical) containing:
Active: 0.5% permethrin
Excipients: Ethanol, propanol-2-ol, water, propylene glycol, sodium hydrogen phosphate

The total duration of intervention and follow-up for each participant is 15 days, two treatments 9 days apart with a follow-up 2 and 7 days after the first treatment and 2 and 5 days after the second treatment.
Primary outcome measure(s) 1. Number of participants with no evidence of active head louse infestation 14 days (+/- 1 day) after enrolment
2. Safety, assessed 2 and 7 days after the first treatment, and 2 and 5 days after the second treatment
Secondary outcome measure(s) 1. Ease of application (investigator opinion), assessed using a questionnaire on the same day as the first treatment
2. Participant acceptability, assessed using a questionnaire 5 days after the second treatment
Sources of funding Omega Pharma N.V. (Belgium)
Trial website
Publications 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/19343362
Contact name Mr  Ian  Burgess
  Address Medical Entomology Centre
Insect Research & Development Limited
Cambridge House
Barrington Road
  City/town Royston
  Zip/Postcode SG8 6QZ
  Country United Kingdom
  Tel +44 1763 263011
  Fax +44 1763 263022
  Email ian@insectresearch.com
Sponsor Omega Pharma N.V. (Belgium)
  Address Venecoweg 26
  City/town Nazareth
  Zip/Postcode B-9810
  Country Belgium
  Sponsor website: http://www.omega-pharma.be
Date applied 07/04/2008
Last edited 26/11/2009
Date ISRCTN assigned 29/05/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.